CUE
vs
S&P 500
CUE
S&P 500
Over the past 12 months, CUE has underperformed S&P 500, delivering a return of -74% compared to the S&P 500's +14% growth.
Stocks Performance
CUE vs S&P 500
Performance Gap
CUE vs S&P 500
Performance By Year
CUE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cue Biopharma Inc
Glance View
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 57 full-time employees. The company went IPO on 2018-01-02. The firm is engineering a class of injectable biologics designed to selectively engage and modulate targeted T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. The company has developed Immuno-STAT (Selective Targeting and Alteration of T Cells) platform, which harness an individual's intrinsic immune repertoire for restoring health while avoiding the deleterious side effects of broad immune activation (for immuno-oncology or infectious disease indications) or broad immune suppression (for autoimmunity and inflammation). The company has developed four biologic series within the Immuno-STAT platform, which includes CUE-100, CUE-200, CUE-300 and CUE-400, each specifically designed through rational protein engineering to possess distinct signaling modules for desired biological mechanisms to be applied across many diseases. CUE-101 is its advanced clinical stage asset.
